Lumosa Therapeutics Co., Ltd. announced The LT3001 formulation patent was granted by United States Patent and Trademark Office. The term of patent last until Sept. 2040.

is a novel small molecule indicated for the treatment of acute is chemic stroke. Animal studies have demonstrated LT3001--s multi-function effects include promoting vascular recanalization and reducing reperfusion injury. Multiple Phase 2 clinical trials are underway.

LT3001 received Fast Track Designation from the US FDA in January 2022. The compound patent of LT3001 was filed in 18 countries and was already granted in 17 countries, including major countries such as Taiwan, the United States, China, Europe and South Korea. The formulation patent of LT3001 was filed in 17 counties, including the granted US patent mentioned in this statement.

The applications in other jurisdictions are under examination. The dosing regimen patent of LT3001 was filed in under PCT (Patent Cooperation Treaty) system. It takes a considerable time to develop a new drug and the cost of development is relatively high.

The success of the development is not guaranteed. The investors shall bear the investment risk and judge the investment with caution.